Development and Validation of the Medical Affairs Pharmaceutical Physician Value (MAPPval) Instrument
Open Access
- 7 January 2022
- journal article
- research article
- Published by Springer Science and Business Media LLC in Pharmaceutical Medicine
- Vol. 36 (1), 47-57
- https://doi.org/10.1007/s40290-021-00413-9
Abstract
Background A pilot study conducted in 2020 suggested that Medical Affairs Pharmaceutical Physicians (MAPPs) may be inherently undervalued within the pharmaceutical industry and vulnerable to replacement by less qualified roles. There are currently no standardized metrics to measure MAPP performance, thus it is necessary to measure the value of MAPPs to employers and clarify the need for their specific skills. Objectives The first aim of this study was to identify a list of indicators to produce an MAPP value measurement tool, and the second aim was to determine its discriminant validity by showing that the ‘MAPPval instrument’ differentiated the MAPP role from other internal stakeholders (regulatory affairs, market access, commercial, and patient advocacy) in terms of accountability for pharmaceutical company activities and level of engagement with external stakeholders. Methods MAPPs were recruited using convenience sampling via professional networks and completed a qualitative online survey to identify a list of key role indicators using a consensus method known as the Jandhyala method. Responses were coded and scored, and aggregated responses were presented to participants in a Consensus Round. Participants rated their agreement with each item on a 5-point Likert scale, from strongly agree to strongly disagree. Indicators that reached a consensus index of > 50% (CI ≥ 0.51) were retained in the final MAPP performance instrument. Participants’ retrospectively self-reported professional activities over a period of 12 months were used to validate the measure. A two-proportion z-test and Mann–Whitney tests were used to determine discriminant validity by showing whether the value of the MAPP role as defined by the instrument was significantly different from that of other internal stakeholders in terms of their accountability for and external stakeholder benefit from each MAPP activity. Results In total, 11 MAPPs participated in the Jandhyala method, which generated 22 unique MAPP value indicators. Payor-targeted activities and journal publications had the two highest awareness indexes (1.00 and 0.98, respectively). The retrospective study confirmed the MAPPval instrument’s validity. MAPPs were the only internal stakeholder classified as accountable for at least one activity that benefited all four stakeholders. They were classified as accountable for activities that influenced significantly more external stakeholders than other internal stakeholders, even when activities influenced fewer than four external stakeholders. MAPPs were also accountable for significantly more activities recorded over the 12-month period than regulatory affairs, market access, commercial, and patient advocacy. Conclusions This study generated and validated the first measure of MAPP value to pharmaceutical companies. MAPPs have unique value to pharmaceutical companies compared with other roles in terms of their accountability for activities that influence regulators, payors, prescribers, and patients. Through their accountability for pharmaceutical company activities and influence of external stakeholders, MAPPs play a key role in medicine adoption.Keywords
This publication has 30 references indexed in Scilit:
- Doctors' knowledge, attitudes, and compliance with 2013 ACC/AHA guidelines for prevention of atherosclerotic cardiovascular disease in SingaporeVascular Health and Risk Management, 2015
- Interprofessional collaboration in research, education, and clinical practice: working together for a better futureJournal of Chiropractic Education, 2015
- Core competencies for pharmaceutical physicians and drug development scientistsFrontiers in Pharmacology, 2013
- American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the Prevention and Early Detection of Cervical CancerAmerican Journal of Clinical Pathology, 2012
- Following Cancer Prevention Guidelines Reduces Risk of Cancer, Cardiovascular Disease, and All-Cause MortalityCancer Epidemiology, Biomarkers & Prevention, 2011
- Pharmaceutical MedicineInternational Journal of Pharmaceutical Medicine, 2007
- Gaps between knowing and doing: Understanding and assessing the barriers to optimal health careJournal of Continuing Education in the Health Professions, 2007
- Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER surveyEuropean Heart Journal, 2005
- Gaps between best evidence and practice: causes for concernThe Medical Journal of Australia, 2004
- Australian healthcare reform: in need of political courage and champions.The Medical Journal of Australia, 2004